This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
of the outcome measures was 7 to 9 days after discharge, the exceptions being biomedical physiologic outcomes and relapse free survival, for which the follow up was 8 weeks. No loss to follow up was reported.
Analysis of effectiveness
The principal (intention to treat or treatment completers only) used in the effectiveness study was not explicitly reported. The health outcome measures adopted in the study were quality of life (QOL) gauged by the standardised Medical Outcomes Study (MOS) SF-36 instrument using research interviewers not involved in patient care, clinical status represented by peak flow rates,and relapse free survival. The groups were shown to be comparable in terms of demographic and clinical variables, and in terms of QOL measured at baseline. A multivariate analysis was performed to investigate the relationship between interventions and health outcomes, controlling for confounding variables.
Effectiveness results
According to MOS SF-36 domains, the EDOU group had better scores in: In terms of the remaining MOS SF-36 domains, there were no significant differences between the groups. The multivariate analysis established the predictive power of EDOU treatment on higher QOL in terms of six domains. The peak flow rate was 62% (9.7%) for the EDOU group against 59% (17.1%) for the inpatient group (p=0.189). The relapse free survival rate was 58%for both groups (p=0.74).
Clinical conclusions
The study revealed the efficacy of the treatment in the EDOU in improving the QOL of patients with acute asthma compared with standard inpatient care.
Measure of benefits used in the economic analysis
No summary measure was identified in the economic study and only separate clinical outcomes were reported.
Direct costs
Resource utilisation was not reported separately from costs. Cost items were not reported separately. The cost analysis included the fixed costs (personnel salaries, benefits, equipment, building costs, utilities, contracts, and malpractice) and variable costs (medications, reagents, supplies, paper, and food). The resource use associated with each patient was extracted from the medical charts. The unit costs of resource used were calculated. Cost data for all items except costs of labour, which were determined by work sampling, were obtained from hospital financial records. The perspective adopted in the cost analysis was not clearly reported. The cost calculations were based on intention to treat. The date of the price data was not specified.
